The pharmacokinetics of
marbofloxacin was studied in eight healthy female Beagle dogs before and after moderate renal impairment was induced experimentally. A single intravenous (i.v.) administration and repeated administration for 8 days (2 mg/kg, once-a-day) of
marbofloxacin were studied. Renal impairment was induced by a right kidney
nephrectomy and
electrocoagulation of the left kidney. An increase (P < 0.001) in the plasma concentrations of
urea (from 3.8+/-0.7 to 9.8+/-2.1 mmol/L) and
creatinine (from 78.8+/-3.4 to 145.8+/-22.3 micromol/L), and a significant decrease (2.9+/-0.3 vs 1.5+/-0.2 mL/kg/min) (P < 0.001) in glomerular filtration rate were observed in the renal-impaired dogs. The clearance of
marbofloxacin was slightly decreased after the induction of
renal failure (1.6+/-0.2 to 1.4+/-0.1 mL/kg/min) (P < 0.05), but no significant variation of volume of distribution at steady state (Vss) and mean residence time (MRT) was observed after
intravenous administration of
marbofloxacin (P > 0.05). Following
oral administration of
marbofloxacin, an increase in total area under the concentration time curve (AUC) was observed after
renal failure (from 10372+/-1710 to 11459+/-1119 mg x min/L) (P < 0.05), but indices of accumulation were not modified. An increase (P < 0.01) in the AUC of N-
oxide-
marbofloxacin was observed after surgery. In conclusion, renal impairment has no biologically relevant influence on
marbofloxacin disposition and there is no need for dosage adjustment of
marbofloxacin in dogs with mild renal impairment.